Vijaya Diagnostic Centre Ltd (VIJAYA)
🎯 Key Takeaways
- Vijaya Diagnostic Centre is in a high-growth expansion phase, leveraging its asset-light hub-and-spoke model to scale diagnostics services across tier-2 and tier-3 cities. Management is targeting sustainable high double-digit growth through strategic network expansion, with profitability remaining resilient despite scale-up.
- Revenue grew 5.3% QoQ to ₹231 in Q1FY27.
- ⚠️ Execution risk in scaling new hubs across multiple cities without margin erosion.
📖 The Story
Vijaya Diagnostic Centre is in a high-growth expansion phase, leveraging its asset-light hub-and-spoke model to scale diagnostics services across tier-2 and tier-3 cities. Management is targeting sustainable high double-digit growth through strategic network expansion, with profitability remaining resilient despite scale-up. The company maintains a strong balance sheet with zero debt and robust returns on equity and capital.
📰 What's Happening
In Q1 FY27, Vijaya reported 22.8% YoY revenue growth to INR 2,300 crores, driven by 16.5% volume expansion and 34% YoY EBITDA growth to INR 98 crores with a healthy 42.7% margin. PAT rose 37.6% to INR 53 crores, supported by 92% B2C revenue contribution and INR 503 revenue per test. The company commissioned 2 new hubs and 6 spokes, expanding its network to 51 hubs and 115 spokes. Management plans for 15 new hubs across Pune, Bangalore, and Kolkata, backed by INR 190-195 crores of capex, including INR 190 crores for land acquisition in Andhra Pradesh. No margin compression is expected despite expansion, reflecting operational leverage and pricing discipline.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 202 | 205 | 219 | 231 |
| Operating Profit | 60 | 62 | 71 | 73 |
| OPM % | 29.6% | 30.1% | 32.5% | 31.8% |
| Net Profit | 43 | 43 | 48 | 53 |
| EPS | ₹4.21 | ₹4.20 | ₹4.66 | ₹5.16 |
Revenue has grown consistently over the past four quarters, rising from INR 202 crores in September 2025 to INR 231 crores in June 2026, with OPM holding firm above 30% and EBITDA margins expanding to 42.7%. Net profit and EPS have tracked this trend, increasing from INR 43 crores (EPS: ₹4.21) in September 2025 to INR 53 crores (EPS: ₹5.16) in June 2026. This profitability trajectory aligns with management’s focus on high-margin B2C services and operational efficiency, even as network expansion accelerates.
🔮 Management Outlook & What's Next
Management expects no margin compression in FY26 despite network expansion and targets sustainable high double-digit growth. It plans to commission 15 new hubs across key cities, including Pune, Bangalore, and Kolkata, as part of a tier-2 expansion strategy. Capex of INR 190-195 crores is allocated for land acquisition and infrastructure development, with land in Andhra Pradesh already secured at INR 190 crores. The company emphasizes scalability and profitability retention as core pillars of its growth model.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 |
| Reserves | 715 | 785 | 855 | 947 |
| Borrowings | 292 | 0 | 365 | 423 |
| Total Liabilities | 1,125 | 1,274 | 1,391 | 1,507 |
| Fixed Assets | 664 | 865 | 843 | 930 |
| Investments | 160 | 185 | 229 | 228 |
| Total Assets | 1,125 | 1,274 | 1,391 | 1,507 |
The balance sheet shows a strong capital structure with zero net borrowings and growing equity and reserves. Total assets rose to INR 1,507 crores as of March 2026 from INR 1,391 crores a year earlier, driven by network expansion and investments. Equity increased to ₹957 crores (including reserves), while borrowings remained stable at ₹423 crores, indicating that growth is being funded through internal cash flows and equity rather than debt. This supports a conservative and sustainable expansion strategy.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 | Mar 2026 |
|---|---|---|
| Operating | +224 | +271 |
| Investing | -182 | -174 |
| Financing | -52 | -69 |
| Net Cash Flow | -9 | +27 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 52.6% | 52.6% | 52.5% | 52.5% |
| FII | 18.3% | 15.1% | 13.4% | 11.7% |
| DII | 25.3% | 28.6% | 29.9% | 31.6% |
| Public | 3.2% | 3.1% | 3.5% | 3.5% |
| # Shareholders | 58,994 | 57,784 | 62,946 | 67,251 |
Institutional investor interest has risen significantly, with FII holdings increasing from 11.66% in Q1 FY27 to 13.38% in Q4 FY26 and peaking at 15.1% in Q3 FY26, before settling at 11.66% in the latest filing. DII holdings have declined slightly from 31.61% to 29.93%, while promoter holding remains stable at 52.51%. The growing institutional stake reflects confidence in the company’s growth trajectory, though the recent stabilization in FII allocation may warrant monitoring for potential volatility.
⚖️ Peer Comparison — Healthcare
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| APOLLOHOSP | 1.27 L Cr | 60.9 | 22.1% | 22.9% | 0.60 |
| MAXHEALTH | 1.01 L Cr | 69.2 | 14.4% | 13.6% | 0.27 |
| MANIPALHOS | 94,201 | — | — | — | 1.25 |
| FORTIS | 66,987 | 63.9 | 13.3% | 10.8% | 0.29 |
| ASTERDM | 66,504 | 123.5 | 12.9% | 8.6% | 0.17 |
| MEDANTA | 38,921 | 69.9 | 21.9% | 16.3% | 0.10 |
| NH | 38,161 | 46.5 | 13.7% | 18.0% | 1.07 |
| KIMS | 32,292 | 150.8 | 9.7% | 8.7% | 1.44 |
| LALPATHLAB | 32,009 | 46.0 | 29.6% | 21.8% | 0.00 |
| POLYMED | 17,610 | 55.9 | 15.1% | 11.3% | 0.06 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Execution risk in scaling new hubs across multiple cities without margin erosion. 2. Competitive pressure in the diagnostics space as new entrants expand into tier-2 markets. 3. Regulatory and pricing headwinds in pathology services, which could impact revenue per test. 4. Governance risk following the resignation of the Company Secretary and Compliance Officer, potentially affecting compliance oversight during a period of rapid expansion.
📋 Recent Filings
-
🔴 Financial Results 11 September 2026Vijaya Diagnostic Centre announced its acquisition of Arya Wellness Centre in Guwahati for approximately ₹46 crore via slump sale, targeting entry int...
-
🟡 Board Meeting 11 September 2026Vijaya Diagnostic Centre announced it will acquire Arya Wellness Centre's integrated diagnostic business in Assam for ₹46.20 crores cash via slump sal...
-
🔴 Announcement 11 September 2026Vijaya Diagnostic Centre announced its acquisition of Arya Wellness Centre in Guwahati for approximately ₹46 crore via a slump sale, marking its entry...
-
🔴 Announcement 2 September 2026Vijaya Diagnostic Centre announced the appointment of Dr. Venkata Naresh Yallapragada as Chief Information Officer effective September 2, 2026, bringi...
-
🔴 Announcement 2 September 2026Vijaya Diagnostic Centre Ltd announced its schedule for an analyst and institutional investor meeting on September 10, 2026, hosted by Emkay Global in...
-
Announcement 26 August 2026Vijaya Diagnostic Centre announced the resignation of Ms. Naga Vasudha Tadepalli as Company Secretary and Compliance Officer, effective close of busin...
-
🔴 Corporate Action 26 August 2026Vijaya Diagnostic Centre announced a final dividend of ₹2 per share for FY 2025-26, payable to shareholders on record as of September 16, 2026, follow...
-
🔴 annual report 26 August 2026Vijaya Diagnostic Centre Limited announced that it has sent web-link letters to shareholders without registered email addresses, providing the exact p...
-
🔴 Announcement 26 August 2026Vijaya Diagnostic Centre announced the resignation of Ms. Naga Vasudha Tadepalli as Company Secretary and Compliance Officer, effective close of busin...
-
🟡 Board Meeting 26 August 2026No summary available
🧠 Analyst's Read
Vijaya Diagnostic Centre is executing a disciplined expansion strategy with strong profitability and institutional backing, but its growth trajectory hinges on flawless execution of network rollout and sustained pricing power. Investors should monitor margin trends in new hubs and the pace of capex deployment relative to revenue growth.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-13.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when VIJAYA files new disclosures
Track VIJAYA filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track VIJAYA — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd